| Title | Phase II AIDS Malignancy Consortium trial of topical halofuginone in AIDS-related Kaposi sarcoma. |
| Publication Type | Journal Article |
| Year of Publication | 2011 |
| Authors | Koon HB, Fingleton B, Lee JY, Geyer JT, Cesarman E, Parise RA, Egorin MJ, Dezube BJ, Aboulafia D, Krown SE |
| Journal | J Acquir Immune Defic Syndr |
| Volume | 56 |
| Issue | 1 |
| Pagination | 64-8 |
| Date Published | 2011 Jan 01 |
| ISSN | 1944-7884 |
| Keywords | Administration, Topical, Adult, AIDS-Related Opportunistic Infections, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Piperidines, Quinazolinones, Sarcoma, Kaposi, Single-Blind Method, Young Adult |
| Abstract | Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. Serial Kaposi sarcoma biopsies assessed treatment effects on angiogenic factors and Kaposi sarcoma herpesvirus-latency associated nuclear antigen-1 (KSHV-LANA). We observed marked heterogeneity of KSHV-LANA expression. Although the small number of subjects whose response could be evaluated precluded definitive assessment of halofuginone's efficacy, we observed a significant decrease in type-I collagen only in halofuginone-treated lesions, but no effect on MMP-2. The trial design is applicable to future studies of topical agents. |
| DOI | 10.1097/QAI.0b013e3181fc0141 |
| Alternate Journal | J Acquir Immune Defic Syndr |
| PubMed ID | 21068672 |
| Grant List | UO1 CA121947 / CA / NCI NIH HHS / United States |
Related Faculty:
Ethel Cesarman, M.D., Ph.D. Julia Geyer, M.D.